Увійти

Готові списки джерел за темами / 305.5/2/0973 / Статті в журналах

Статті в журналах з теми "305.5/2/0973"

Щоб переглянути інші типи публікацій з цієї теми, перейдіть за посиланням: 305.5/2/0973.

Автор: Grafiati

Опубліковано: 26 липня 2024

Оновлено: 29 липня 2024

Оформте джерело за APA, MLA, Chicago, Harvard та іншими стилями

Оберіть тип джерела:

Ознайомтеся з топ-50 статей у журналах для дослідження на тему "305.5/2/0973".

Біля кожної праці в переліку літератури доступна кнопка «Додати до бібліографії». Скористайтеся нею – і ми автоматично оформимо бібліографічне посилання на обрану працю в потрібному вам стилі цитування: APA, MLA, «Гарвард», «Чикаго», «Ванкувер» тощо.

Також ви можете завантажити повний текст наукової публікації у форматі «.pdf» та прочитати онлайн анотацію до роботи, якщо відповідні параметри наявні в метаданих.

Переглядайте статті в журналах для різних дисциплін та оформлюйте правильно вашу бібліографію.

1

Gómez-Amo, J. L., V. Estellés, A. di Sarra, R. Pedrós, M. P. Utrillas, J. A. Martínez- Lozano, C. González-Frias, E. Kyrö, and J. M. Vilaplana. "Operational considerations to improve total ozone measurements with a Microtops II ozone monitor." Atmospheric Measurement Techniques 5, no. 4 (April 19, 2012): 759–69. http://dx.doi.org/10.5194/amt-5-759-2012.

Повний текст джерела

Анотація:

Abstract. A Microtops II "ozone monitor" with UV channels centered at 305.5, 312.5, and 320 nm has been used routinely in six experimental campaigns carried out in several geographic locations and seasons, covering latitudes from 35 to 68° N during the last ten years (2001–2011). The total ozone content is retrieved by Microtops II by using different combinations (Channel I, 305.5/312.5 nm; Channel II, 312.5/320 nm; and Channel III, 305.5/312.5/320 nm) of the signals at the three ultraviolet wavelengths. The long-term performance of the total ozone content determination has been studied taking into account the sensitivities to the calibration, airmass, temperature and aerosols. When a calibration was used and the airmass limit was fixed to 3, the root mean square deviations of the relative differences produced by Microtops II with respect to several Brewers are 0.9, 2, and 2% respectively for the Channel I, Channel II, and Channel III retrieval. The performance of the Microtops retrieval has been stable during the last ten years. Channel I represents the best option to determine the instantaneous total ozone content. Channels II and III values appear weakly sensitive to temperature, ozone content, and aerosols. Channel II is more stable than Channel I for airmasses larger than 2.6. The conclusions do not show any dependence on latitude and season.

Стилі APA, Harvard, Vancouver, ISO та ін.

2

LoRusso, Patricia, Geoffrey Shapiro, Shuchi Sumant Pandya, Eunice Lee Kwak, Cheryl Jones, Marcia Belvin, Luna C. Musib, et al. "A first-in-human phase Ib study to evaluate the MEK inhibitor GDC-0973, combined with the pan-PI3K inhibitor GDC-0941, in patients with advanced solid tumors." Journal of Clinical Oncology 30, no. 15_suppl (May 20, 2012): 2566. http://dx.doi.org/10.1200/jco.2012.30.15_suppl.2566.

Повний текст джерела

Анотація:

2566 Background: Both RAS/RAF/MEK and PI3K/Akt signaling pathways are deregulated in many tumor types. Targeting both pathways may be more efficacious than targeting either pathway alone. In preclinical models, concurrent administration of GDC‑0973, a potent, selective, MEK1/2 inhibitor and GDC-0941, a potent class I PI3K inhibitor, shows improved efficacy compared to either agent alone dosed continuously or intermittently. Methods: A phase Ib dose-escalation study with 3+3 design was initiated in patients (pts) with advanced solid tumors to evaluate the safety and pharmacokinetics (PK) of oral dosing of GDC-0973 and GDC-0941. Pts received: concurrent GDC-0973 + GDC-0941 once daily (qd) on a 21 day on/7 day off (21/7) schedule; intermittent GDC-0973 on Days 1, 4, 8, 11, 15, 18 of a 28 day cycle + GDC-0941 qd on a 21/7 schedule (MEK int); or GDC-0973 + GDC-0941 qd on a 7 day on /7 day off schedule (7/7). Starting doses were 20 mg GDC-0973 + 80 mg GDC-0941 (21/7), 100 mg GDC-0973 + 130 mg GDC-0941 (MEK int); 40 mg GDC-0973 + 130 mg GDC-0941 (7/7). Serial plasma PK samples, FDG-PET, and CT scans were obtained. Results: 78 pts have enrolled. DLTs were G3 lipase (n=1), G4 CPK elevation (n=1). Compared to the 21/7 MTD of 40 mg GDC-0973 + 100 mg GDC-0941, higher doses of GDC-0973 + GDC-0941 were tolerated on the MEK int schedule. Overall, adverse events related to the study drug combination in ≥ 20% pts were diarrhea, rash, nausea, fatigue, vomiting, decreased appetite, dysgeusia, and elevated CPK. Preliminary analysis indicated PK of GDC-0973 and GDC-0941 are not altered when dosed in combination. Of 46 evaluable pts, 26 had an FDG-PET partial metabolic response (≥ 20% decrease in mean SUVmax from baseline) at ≥1 time points. Partial responses were observed in 3 pts (mBRAF melanoma, mBRAF pancreatic ca, mKRAS endometrioid ca); 5 pts had stable disease ≥ 5 months. Conclusions: Combination dosing of GDC‑0973 and GDC-0941 is generally well tolerated, with toxicities similar to those observed in single agent GDC-0973 and GDC-0941 phase 1 trials. There are early signs of anti-tumor activity. Dose escalation on MEK int and 7/7 schedules continues and updated data will be presented.

Стилі APA, Harvard, Vancouver, ISO та ін.

3

Padua, Rose Ann, Laure Sarda-Mantel, Mathieu Chiquet, Claire Kappel, Patricia Krief, Niclas Setterblad, Fortune Hontonnou, et al. "BCL-2 Inhibitor Venetoclax (ABT-199) and MEK Inhibitor GDC-0973 Synergise to Target AML Progenitors and Overcome Drug Resistance with the Use of PET Scanning in a Mouse Model of HR-MDS to Monitor Response to Treatment." Blood 132, Supplement 1 (November 29, 2018): 5497. http://dx.doi.org/10.1182/blood-2018-99-114212.

Повний текст джерела

Анотація:

Abstract Introduction: Targeted drugs are needed for HR-MDS/AML, particularly in elderly patients and Venetoclax, approved for some CLL, gives promising results in elderly AML. Assays to predict response to treatment may enable us to deliver personalized treatment. We sought to determine the most informative assay to predict response; viability assays can directly measure the effects of reagents on growth. Progenitor assays can potentially determine if the reagents can target diseased primitive cells. PET scanning can be used to follow response to treatment. Methods: Peripheral blood (PB) or bone marrow (BM) from 7 MDS/AML patients were incubated in a) no treatment, b) ABT-199 (1 µM) (Abbvie), c) GDC-0973 (1 µM) (Genentech) or d) ABT-199+GDC-0973 (1 µM of each) and assessed for viability using the MTT assay (n=2); cell death followed using the Incucyte® Zoom System (Essen Bioscience) (n=2) or methocult progenitor assays (Stem Cell Technologies) (n=4). Having shown that RAS:BCL-2 co-localization correlated with prognosis in MDS/AML patients (Leuk Res 37:312-9, 2013), immunofluorescence was undertaken. A micro PET device dedicated to mice was used to measure BM blast proliferation. After injection of 18F-FLT(a thymidine analogue) in mice untreated (n=7) or ABT-199 (75mg/kg)+GDC-0973(10mg/kg) treated (n=5) normal FVB/N, HR-MDS mice treated with vehicle (n=4), 2-month old HR-MDS before (n=5) and 3-month old before (n=4) and after ABT-199 (75mg/kg)+GDC-0973(10mg/kg) treatment (n=8), PET imaging was performed (Inveon Siemens Medical Systems), analyzed for signal and quantified. Results: Patient details and results are summarized on Table 1. Using the MTT assay 2 PB patient samples were found to be sensitive to ABT-199 treatment (Figure 1A, AS, p=0.00042 and YA, 0.00002) and more sensitive to the combination compared to untreated (AS, p=0.00007 and YA, 0.000003). With the incucyte the BM of one patient (AE) was found to be resistant to both ABT-199 and GDC-0973, but sensitive to the combination (Figure 1B). PB and BM from patient JA were assayed for apoptosis with the incucyte and were found to be sensitive to ABT-199 with increased apoptosis, resistant to GDC-0973 with decreased apoptosis and sensitive to the combination. Four bone marrow samples were tested in the 4 conditions using the progenitor assay (Figure 1C). Three patients were sensitive to GDC-0973, inhibiting any colony formation and the fourth had reduced colony numbers. In this assay patient JA appeared to be sensitive to GDC-0973 treatment whereas the incucyte assay scored this sample to be resistant to apoptosis; thus the cytotoxic effects of GDC-0973 may not be via apoptopsis. As the progenitor assay is likely to score the primitive disease population, this assay may prove more informative than the others without prior selection. One patient (DH) was clearly resistant to ABT-199, whereas the other three (JA, CB and FL) had reduced colony growth. All patients were sensitive to the combination treatment and inhibited colony growth. The RAS:BCL-2 co-localization in the PB revealed no complex in either the Mito or PM upon treatment with ABT-199 alone and some localization in the Mito with GDC-0973. With both ABT-199 and GDC-0973, there were hardly any cells confirming the cytotoxic effects of the combination. As we have previously shown that PM co-localization of the complex is associated with drug resistance (Blood 130:2613, 2017Suppl), we used the combination on our HR-MDS mouse model, where the complex co-localizes in the PM and followed the mice by PET scanning (Figure 1D). Weak signal was visualized in the femurs of untreated and ABT-199+GDC-0973 treated FVB/N mice (FBR 1.17+/-0.34 and 1.02+/-0.08 respectively). Mild PET signal was seen in the femurs of 2 month-old HR-MDS mice, (FBR 1.79+/-0.98). Intense PET signal was seen in the femurs and proximal humerus of HR-MDS mice treated with vehicle (3 month-old, FBR=2.35+/-1.32). Low PET signals were seen in the femurs of 5/8 HR-MDS mice treated with ABT-199+GDC-0973 (FBR=1.93+/-0.84). FBRs of the 3 groups of HR-MDS mice were significantly higher than those of FBV/N groups. Conclusion: Combined Venetoclax (ABT-199) and GDC-0973 targets MDS/AML progenitors and can potentially overcome drug resistance with the disruption of the RAS:BCL-2 complex. Bone marrow disease progression in HR-MDS mice can be monitored with 18F-FLT-PET imaging; PET data shows that the combination slows down disease progression. Disclosures Padua: Abbvie: Research Funding; Genentech: Research Funding. Giraudier:Novartis: Research Funding. Konopleva:Stemline Therapeutics: Research Funding. Andreeff:Oncoceutics: Equity Ownership, Membership on an entity's Board of Directors or advisory committees; United Therapeutics: Patents & Royalties: GD2 inhibition in breast cancer ; Reata: Equity Ownership; Celgene: Consultancy; Jazz Pharma: Consultancy; Oncolyze: Equity Ownership; Amgen: Consultancy, Research Funding; Eutropics: Equity Ownership, Membership on an entity's Board of Directors or advisory committees; Aptose: Equity Ownership, Membership on an entity's Board of Directors or advisory committees; Daiichi-Sankyo: Consultancy, Patents & Royalties: MDM2 inhibitor activity patent, Research Funding; SentiBio: Equity Ownership; Astra Zeneca: Research Funding.

Стилі APA, Harvard, Vancouver, ISO та ін.

4

Ali Khan, Mohd Wajid. "Optimization of methods for peripheral blood mononuclear cells isolation and expansion of human gamma delta T cells." Bioinformation 17, no. 3 (March 31, 2021): 460–70. http://dx.doi.org/10.6026//97320630017460.

Повний текст джерела

Анотація:

Human Vγ9/Vδ2 T cells (γδ T cells) are immune surveillance cells both in innate and adaptive immunity and are a possible target for anticancer therapies, which can induce immune responses in a variety of cancers. Small non-peptide antigens such as zoledronate can do activation and expansion of T cells in vitro. It is evident that for adoptive cancer therapies, large numbers of functional cells are needed into cancer patients. Hence, optimization of methods needs to be carried out for the efficient expansion of these T cells. Standardization of peripheral blood mononuclear cells (PBMCs) isolation was devised. Cytokines (interleukin 2 (IL-2) and interleukin 15 (IL-15)) and zoledronate were also standardized for different concentrations. It was found that an increased number of PBMCs were recovered when washing was done at 1100 revolution per minute (rpm). Significantly high expansion fold was (2524 ± 787 expansion fold) achieved when stimulation of PBMCs was done with 1 μM of zoledronate and both cytokines IL-2 and IL-15 supported the expansion and survival of cells ISSN 0973-2063 (online) 0973-8894 (print) Bioinformation 17(3): 460-469 (2021) ©Biomedical Informatics (2021) 461 at the concentrations of 100 IU/ml and 10 ng/ml respectively. 14-day cultures showed highly pure (91.6 ± 5.1%) and live (96.5 ± 2.5%) expanded γδ T cells. This study aimed to standardize an easy to manipulate technique for the expansion of γδ T cells, giving a higher yield.

Стилі APA, Harvard, Vancouver, ISO та ін.

5

Ranjbar, M., E. Aghaie, M. R. Hosseini, Mohammad Pazouki, and F. Ghavipanjeh. "Optimization of Kaolin Bioleaching by Aspergillus niger." Advanced Materials Research 20-21 (July 2007): 115–18. http://dx.doi.org/10.4028/www.scientific.net/amr.20-21.115.

Повний текст джерела

Анотація:

In this paper, a central composite design was applied to optimize the bioleaching of iron from a kaolin sample containing 2.2% iron impurity by Aspergillus niger isolated from pistachio shell. The strains were inoculated into 500 ml flasks containing 100 ml media consisted of (g/l): sucrose 120; NH4NO3 0.45; KH2PO4 0.1; MgSO4.7H2O 0.3; FeSO4.7H2O 10-4; ZnSO4.7H2O 25×10- 5. The effects of initial pH, sugar and spore concentrations on iron removal extent were investigated. The two-level factorial design points were pH 2 and 5, sugar conc. 70 g/l and 130 g/l, spore conc. 9×107 and 35×107 spores/l. Also, the increase of dissolved iron, oxalic acid concentration, changes in pH value, and sugar concentration were registered. Consequently, after 10 days, the iron concentration of the best condition reached to 179.3 ppm that means 38.8% of the total iron content is removed. Furthermore, the data analysis showed that all the factors are significant, and the iron removal extent increases by increasing the initial pH to 4.4, sucrose content to 93.8 g/l, and spore concentration to 305.5 spores/μl, but further increase in each factor value has negative effect on the response.

Стилі APA, Harvard, Vancouver, ISO та ін.

6

Anandakumar, K., and P. Veerasundari. "Simultaneous Estimation of Paracetamol, Ambroxol Hydrochloride, Levocetirizine Dihydrochloride, and Phenylephrine Hydrochloride in Combined Tablet Formulation by First-Order Derivative Spectrophotometry." ISRN Spectroscopy 2014 (March 30, 2014): 1–8. http://dx.doi.org/10.1155/2014/248960.

Повний текст джерела

Анотація:

Paracetamol, ambroxol hydrochloride, levocetirizine dihydrochloride, and phenylephrine hydrochloride are used in combination for the treatment of chronic sinusitis, rhinitis, fever, nasal discharge, sore throat, and wheezing. The present work deals with method development for simultaneous estimation of paracetamol, ambroxol hydrochloride, levocetirizine dihydrochloride, and phenylephrine hydrochloride in tablet formulation by first-order derivative spectrosphotometry. For determination of sampling wavelength, 10 μg/mL of each of paracetamol, ambroxol hydrochloride, levocetirizine dihydrochloride, and phenylephrine hydrochloride was scanned in 200–400 nm ranges and sampling wavelengths were found to be 305.5 nm for paracetamol, 321 nm for ambroxol hydrochloride, 244 nm for levocetirizine dihydrochloride, and 280 nm for phenylephrine hydrochloride in first-order derivative spectrophotometry. In this method, linearity was observed in the ranges of 20–140 μg/mL for paracetamol and 10–70 μg/mL for ambroxol hydrochloride, levocetirizine dihydrochloride, and phenylephrine hydrochloride. The % recovery was within the range between 98 and 102%, and % relative standard deviation for precision and accuracy of the method was found to be less than 2%. The method is validated as per International Conference on Harmonization Guidelines. The method can be successfully applied for the simultaneous analysis of these drugs in pharmaceutical dosage forms.

Стилі APA, Harvard, Vancouver, ISO та ін.

7

Lieven, Elena V. M., Julian M. Pine, and Helen Dresner Barnes. "Individual differences in early vocabulary development: redefining the referential-expressive distinction." Journal of Child Language 19, no. 2 (June 1992): 287–310. http://dx.doi.org/10.1017/s0305000900011429.

Повний текст джерела

Анотація:

ABSTRACTThe existence of stylistic variation between children in the early stages of language acquisition has been most frequently studied using Nelson's 0973) referential—expressive distinction. While the use of this distinction has generated a great deal of interesting research, there are a number of major problems associated with it. The present study presents a simple scheme, based on formal categories, for coding stylistic variation in the early lexicon. When applied to the first 50 and 100 words of 12 children collected between 0; 11 and 2; 3, the major dimensions of difference are found to be the relative proportion of common nouns and the relative proportion of frozen phrases. Moreover, the proportion of frozen phrases is also found to be significantly positively related to children's early productivity, suggesting that, rather than being a ‘deadend’ in early language development, the acquisition of frozen phrases may provide an alternative route into multiword speech.

Стилі APA, Harvard, Vancouver, ISO та ін.

8

Yue, Qing, Wei Han, and Zi-ling Liu. "Endoscopic reintervention after unilateral metal stent deployment for MHBO using SIS method." Medicine 102, no. 30 (July 28, 2023): e34467. http://dx.doi.org/10.1097/md.0000000000034467.

Повний текст джерела

Анотація:

Endoscopic biliary drainage is the main treatment for unresectable malignant hilar biliary obstruction (MHBO). Recurrent biliary obstruction (RBO) often occurs after unilateral metal stent deployment. Endoscopic reintervention can be complex for this problem, especially for drainage of the contralateral bile duct. The stent-in-stent (SIS) method is a possible solution to this problem. Our objective was to evaluate the safety and feasibility of the SIS method for endoscopic reintervention in patients with RBO due to MHBO after unilateral metal stent deployment. Eleven patients with MHBO received endoscopic reintervention using the SIS method to manage RBO after unilateral metal stent deployment. Clinical data, including technical and clinical success, procedure time, adverse events and complications, stent patency, RBO of the revisionary stent, and survival time were recorded. Nine patients (82%) achieved technical success, and all 9 of them also achieved clinical success. The 2 unsuccessful cases received percutaneous transhepatic cholangial drainage. The median procedure time was 73 minutes. The 3 adverse events were post-endoscopic retrograde cholangiopancreatography pancreatitis, cholangitis, and liver abscess. 6 patients (67%) experienced RBO of the revisionary stent, the median time to RBO of the revisionary stent was 95.5 days, the median survival time after reintervention was 111 days, and the median overall survival time was 305.5 days. Endoscopic reintervention after previous unilateral metal stent deployment using the SIS method appears to be safe and technically feasible for MHBO patients who experience RBO.

Стилі APA, Harvard, Vancouver, ISO та ін.

9

Kerins, Paul J., Roger A. Vertrees, Karen A. Finn, Jonathan H. Cilley, and Anthony J. DelRossi. "Comparison of Two Colloid Constituents in Prime Solutions and the Effect on Blood Loss Following Cardiopulmonary Bypass." Journal of ExtraCorporeal Technology 21 (1989): 11–14. http://dx.doi.org/10.1051/ject/198921s011.

Повний текст джерела

Анотація:

A retrospective study was conducted on a population of 24 patients who had undergone coronary artery bypass grafting (CABG) with cardiopulmonary bypass (CPB). This population is divisible into two groups that differ in prime constituents. Group A used 500cc of 6% Hydroxyethyl starch (Hespan) as the colloid, and Group B used 150cc of 25% albumin. No statistically significant differences were found in the preoperative demographics. All of these cases were done using the same perfusion technique and equipment. Intraoperative values displayed levels of significant difference (p <.05) between the two groups with respect to 1) bypass platelet count; and 2) greater usage of protamine in Group A. Group A Hespan = Platelet count x 1000/ml was 99.90+/-32.4, Blood loss (cc's) was 1033.3+/-305.5, Protamine:Heparin ratio was 1.41:1.0 +/- .37 Group B Albumin = Platelet count x 1000/ml was 153.84 +/- 34.17; Blood loss was 929.6+/- 105.4; Protamine:Heparin ratio was 1.01:1.0 +/- .43 In the postoperative phase which ended when the chest tube was removed, levels of significant difference were as follows: Group A Hespan = Platelet Ct.#2 x 1000/ml was 124.87 +/- 30.62, Blood loss (cc's) was 1390.25 +/- 405.78, PPF Admin. ratio was 1417 +/- 506.32. Group B Albumin= Platelet count x 1000 ml was 159.71 +/- 41.22; Blood loss= 1087.0 +/- 385.72, PPF Admin. ratio was 875 +/- 291.94. From this study it seems as though there are two factors contributing to the increased blood loss seen in Group A that may result from Hespan usage - the intraoperative and postoperative decreased platelet count and the increased amount of protamine used. Furthermore, Group A patients required substantially more PPF postoperatively.

Стилі APA, Harvard, Vancouver, ISO та ін.

10

Izquierdo, César. "René VIRGOULAY (ed.), Le Christ de Maurice Blondel, Desclée, Paris 2003, 229 pp., 15 x 22, ISBN 2-7189-0973-0." Scripta Theologica 36, no. 1 (November 30, 2017): 336. http://dx.doi.org/10.15581/006.36.13845.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

11

Han, Lina, Qi Zhang, Ce Shi, Joel Leverson, Monique Dail, Darren C. Phillips, Jun Chen, et al. "Concomitantly Targeting BCL-2 with Venetoclax (ABT-199/GDC-0199) and MAPK Signaling with Cobimetinib (GDC-0973) in Acute Myeloid Leukemia Models." Blood 126, no. 23 (December 3, 2015): 2544. http://dx.doi.org/10.1182/blood.v126.23.2544.2544.

Повний текст джерела

Анотація:

Abstract Pro-survival molecules including BCL-2 play critical roles in leukemia transformation and chemoresistance. ABT-199/GDC-0199 (venetoclax) is an orally available BH3-mimetic that binds with high affinity to BCL-2, but lacks affinity for BCL-XL and MCL-1. We have recently demonstrated anti-leukemia potency of venetoclax in acute myeloid leukemia (AML) models (Pan et al. Cancer Discovery 2014). However, venetoclax poorly inhibits MCL-1, causing resistance in leukemia cells that rely on MCL-1 for survival. The RAF/MEK/ERK (MAPK) cascade is a major effector pathway in AML that is activated by upstream mutant proteins such as FLT3, KIT and RAS. Additionally, the MAPK pathway regulates BCL-2 family proteins by stabilizing anti-apoptotic MCL-1 and inactivating pro-apoptotic BIM. In this study, we evaluated the anti-tumor effects of concomitant BCL-2 and MAPK blockade by venetoclax in combination with MEK1/2 inhibitor GDC-0973 (cobimetinib).. We initially examined activity of these agents in a panel of myeloid leukemia cell lines with diverse genetic alterations (Fig. 1A). The IC50 values of cobimetinib ranged from < 0.01 µM to > 1 µM after 72 hours of drug treatment but did not correlate with the basal level of p-ERK1/2. In 7 out of 11 cell lines, combination of the agents elicited synergistic growth inhibition. Notably synergism of venetoclax with cobimetinib was observed in venetoclax-resistant cell lines (MOLM14, OCI-AML3, NB4 and THP1). Ongoing analysis of pharmacodynamic markers include transcriptome assessment by RNA sequencing, functional proteomics by reverse phase protein array (RPPA) and quantification of BCL-2:BIM and MCL-1:BIM complexes using the electrochemiluminescent ELISA assay (Meso Scale Discovery, MSD-ELISA). The preliminary MSD data revealed that BCL-2:BIM complex was disrupted in most cell lines and accumulated following cobimetinib treatment, which may be due to the disruption of MCL-1:BIM complex by inhibition of MEK (Fig. 1B). In a long-term culture of primary AML blasts in serum-free stem cell growth medium supplemented with cytokines and StemRegenin 1 (SR1) to main the immature state of leukemia cells, the combination of venetoclax and cobimetinib induced distinct apoptotic cell death, with AML #1 sensitive to venetoclax but resistant to cobimetinib. Alternatively, AML #2 and #3 samples were resistant to venetoclax but sensitive to cobimetinib and the combination of both drugs (Fig. 1C). We next investigated signaling patterns and BCL-2 family protein expression in AML stem/progenitor cells using a 34-antibody panel and time-of-flight mass cytometry (CyTOF). In AML#1, BCL-2 was expressed in leukemia blasts, with enrichment in a progenitor AML population phenotypically defined as CD45dim CD34+ CD38+ CD123+ CD33+ (Fig. 1D). The high expression level of BCL-2 and low expression of MCL-1 and BCL-XL may account for sensitivity to venetoclax in AML#1. Both basal and G-CSF- or SCF-stimulated p-ERK was efficiently down-regulated by cobimetinib; however, G-CSF-evoked p-STAT3/5 and SCF-induced p-AKT were only slightly reduced (Fig. 1E). Notably we observed increased phosphorylation of STAT5 pathway upon treatment with cobimetinib, suggesting that active MAPK signals inhibit phosphorylation of the JAK-STAT pathway, as previously reported (Krasilnikov et al. Oncogene, 2003 and Lee at al. Cancer Cell, 2014). To test the efficacy of both compounds in vivo, we injected NSG mice with genetically engineered OCI-AML3/Luc/GFP cells. Bioluminescent imaging (BLI) demonstrated significantly reduced leukemia burden in treated groups compared to controls, more prominently in the cobimetinib single agent and venetoclax plus cobimetinib co-treated mice (Fig. 1F). The efficacy study is ongoing and median survival for cobimetinib and venetoclax co-treated mice has yet to be determined (Fig. 1G). In summary, our data demonstrates that combinatorial blockade of MAPK and BCL-2 pathways is synergistic in the majority of AML cell lines tested and can overcome intrinsic resistance to venetoclax. Ongoing studies will evaluate efficacy of this combination therapy in primary human AML xenografts and elucidate mechanisms of synergy. Disclosures Leverson: AbbVie: Employment, Equity Ownership. Dail:Genentech: Employment, Equity Ownership. Phillips:AbbVie: Employment, Other: Shareholder, Patents & Royalties. Chen:Abbvie: Employment, Equity Ownership. Jin:Abbvie: Employment, Equity Ownership. Jabbour:Pfizer: Consultancy, Research Funding. Sampath:Genentech: Employment, Equity Ownership. Konopleva:Novartis: Research Funding; AbbVie: Research Funding; Stemline: Research Funding; Calithera: Research Funding; Threshold: Research Funding.

Стилі APA, Harvard, Vancouver, ISO та ін.

12

Porosnicu, Tamara Mirela, Dorel Sandesc, Daniel Jipa, Ciprian Gindac, Cristian Oancea, Felix Bratosin, Roxana Manuela Fericean, et al. "Assessing the Outcomes of Patients with Severe SARS-CoV-2 Infection after Therapeutic Plasma Exchange by Number of TPE Sessions." Journal of Clinical Medicine 12, no. 5 (February 22, 2023): 1743. http://dx.doi.org/10.3390/jcm12051743.

Повний текст джерела

Анотація:

The high mortality risk in severe SARS-CoV-2 infections is tightly correlated to the extreme elevation of inflammatory markers. This acute accumulation of inflammatory proteins can be cleared using plasma exchange (TPE), commonly known as plasmapheresis, although the available data on performing TPE in COVID-19 patients is limited regarding the optimal treatment protocol. The purpose for this study was to examine the efficacy and outcomes of TPE based on different treatment methods. A thorough database search was performed to identify patients from the Intensive Care Unit (ICU) of the Clinical Hospital of Infectious Diseases and Pneumology between March 2020 and March 2022 with severe COVID-19 that underwent at least one session of TPE. A total of 65 patients satisfied the inclusion criteria and were eligible for TPE as a last resort therapy. Of these, 41 patients received 1 TPE session, 13 received 2 TPE sessions, and the remaining 11 received more than 2 TPE sessions. It was observed that IL-6, CRP, and ESR decreased significantly after all sessions were performed in all three groups, with the highest decrease of IL-6 in those who received >2 TPE sessions (from 305.5 pg/mL to 156.0 pg/mL). Interestingly, there was a significant increase in leucocyte levels after TPE, but there was no significant difference in MAP changes, SOFA score, APACHE 2 score, or the PaO2/FiO2 ratio. The ROX index was significantly higher among the patients who underwent more than two TPE sessions, with an average of 11.4, compared to 6.5 in group 1 and 7.4 in group 2, which increased significantly after TPE. Nevertheless, the mortality rate was very high (72.3%), and the Kaplan–Meier analysis identified no significant difference in survival according to the number of TPE sessions. TPE can be used as last resort salvage therapy that can be regarded as an alternative treatment method when the standard management of these patients fails. It significantly decreases the inflammatory status measured via IL-6, CRP, and WBC, as well as demonstrating an improvement of the clinical status measured via PaO2/FiO2, and duration of hospitalization. However, the survival rate does not seem to change with the number of TPE sessions. Based on the survival analysis, one session of TPE as last resort treatment in patients with severe COVID-19 proved to have the same effect as repeated TPE sessions of 2 or more.

Стилі APA, Harvard, Vancouver, ISO та ін.

13

Robbins, Brian L., Edmund V. Capparelli, Ellen G. Chadwick, Ram Yogev, Leslie Serchuck, Carol Worrell, Mary Elizabeth Smith, et al. "Pharmacokinetics of High-Dose Lopinavir-Ritonavir with and without Saquinavir or Nonnucleoside Reverse Transcriptase Inhibitors in Human Immunodeficiency Virus-Infected Pediatric and Adolescent Patients Previously Treated with Protease Inhibitors." Antimicrobial Agents and Chemotherapy 52, no. 9 (September 2008): 3276–83. http://dx.doi.org/10.1128/aac.00224-08.

Повний текст джерела

Анотація:

ABSTRACT Human immunodeficiency virus (HIV)-infected children and adolescents who are failing antiretrovirals may have a better virologic response when drug exposures are increased, using higher protease inhibitor doses or ritonavir boosting. We studied the pharmacokinetics and safety of high-dose lopinavir-ritonavir (LPV/r) in treatment-experienced patients, using an LPV/r dose of 400/100 mg/m2 orally every 12 h (p.o. q12h) (without nonnucleoside reverse transcriptase inhibitor [NNRTI]), or 480/120 mg/m2 p.o. q12h (with NNRTI). We calculated the LPV inhibitory quotient (IQ), and when the IQ was <15, saquinavir (SQV) 750 mg/m2 p.o. q12h was added to the regimen. We studied 26 HIV-infected patients. The median age was 15 years (range, 7 to 17), with 11.5 prior antiretroviral medications, 197 CD4 cells/ml, viral load of 75,577 copies/ml, and a 133-fold change in LPV resistance. By treatment week 2, 14 patients had a viral-load decrease of >0.75 log10, with a median maximal decrease in viral load of −1.57 log10 copies/ml at week 8. At week 2, 19 subjects showed a median LPV area under the concentration-time curve (AUC) of 157.2 (range, 62.8 to 305.5) μg·h/ml and median LPV trough concentration (C trough) of 10.8 (range, 4.1 to 25.3) μg/ml. In 16 subjects with SQV added, the SQV median AUC was 33.7 (range, 4.4 to 76.5) μg·h/ml and the median SQV C trough was 2.1 (range, 0.2 to 4.1) μg/ml. At week 24, 18 of 26 (69%) subjects remained in the study. Between weeks 24 and 48, one subject withdrew for nonadherence and nine withdrew for persistently high virus load. In antiretroviral-experienced children and adolescents with HIV, high doses of LPV/r with or without SQV offer safe options for salvage therapy, but the modest virologic response and the challenge of adherence to a regimen with a high pill burden may limit the usefulness of this approach.

Стилі APA, Harvard, Vancouver, ISO та ін.

14

Behyari, Mahla, Rana Imani, and Hamid Keshvari. "Evaluation of Silk Fibroin Nanofibrous Dressing Incorporating Niosomal Propolis, for Potential Use in Wound Healing." Fibers and Polymers 22, no. 8 (April 26, 2021): 2090–101. http://dx.doi.org/10.1007/s12221-021-0973-2.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

15

Lehrnbecher, Thomas, Stefan Schöning, Luciana Porto, and Jan Sörensen. "Die Langerhanszell-Histiozytose: eine interdisziplinäre Herausforderung." Pädiatrie 29, no. 1 (February 2017): 40–42. http://dx.doi.org/10.1007/s15014-017-0973-2.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

16

Ozeki, Kenta, and Tomoki Yamashita. "Spanning Trees: A Survey." Graphs and Combinatorics 27, no. 1 (September 1, 2010): 1–26. http://dx.doi.org/10.1007/s00373-010-0973-2.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

17

Gu, Yuqi, Tobias Witter, Patty Livingston, Purnima Rao, Terry Varshney, Tom Kuca, and M. Dylan Bould. "The effect of simulator fidelity on acquiring non-technical skills: a randomized non-inferiority trial." Canadian Journal of Anesthesia/Journal canadien d'anesthésie 64, no. 12 (October 6, 2017): 1182–93. http://dx.doi.org/10.1007/s12630-017-0973-2.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

18

Maddaloni, Ernesto, Stephanie D’Eon, Stephanie Hastings, Liane J. Tinsley, Nicola Napoli, Mogher Khamaisi, Mary L. Bouxsein, Savitri M. R. Fouda, and Hillary A. Keenan. "Bone health in subjects with type 1 diabetes for more than 50 years." Acta Diabetologica 54, no. 5 (February 25, 2017): 479–88. http://dx.doi.org/10.1007/s00592-017-0973-2.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

19

Schneider, S. S., and G. DeGrandi-Hoffman. "Queen replacement in African and European honey bee colonies with and without afterswarms." Insectes Sociaux 55, no. 1 (December 4, 2007): 79–85. http://dx.doi.org/10.1007/s00040-007-0973-2.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

20

Pullar, Ben, Catherine Lunter, Jane Collie, Syed Shah, Nimish Shah, Sami Hayek, and Oliver J. Wiseman. "Do renal stones that fail lithotripsy require treatment?" Urolithiasis 45, no. 6 (March 15, 2017): 597–601. http://dx.doi.org/10.1007/s00240-017-0973-2.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

21

Akpinar-Elci, Muge, Francis E. Martin, Joshua G. Behr, and Rafael Diaz. "Saharan dust, climate variability, and asthma in Grenada, the Caribbean." International Journal of Biometeorology 59, no. 11 (February 24, 2015): 1667–71. http://dx.doi.org/10.1007/s00484-015-0973-2.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

22

Kushnir, R. M., M. M. Nykolyshyn, U. V. Zhydyk, and V. M. Flyachok. "On the theory of inhomogeneous anisotropic shells with initial stresses." Journal of Mathematical Sciences 186, no. 1 (August 26, 2012): 61–72. http://dx.doi.org/10.1007/s10958-012-0973-2.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

23

Akiyoshi, Takashi, Toshiaki Watanabe, and Masashi Ueno. "Risk Factors for and Long-term Outcomes of Anastomotic Leakage after Colorectal Cancer Surgery." World Journal of Surgery 35, no. 7 (February 3, 2011): 1689–90. http://dx.doi.org/10.1007/s00268-011-0973-2.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

24

Kreuzer, M., F. Dufey, D. Laurier, D. Nowak, J. W. Marsh, M. Schnelzer, M. Sogl, and L. Walsh. "Mortality from internal and external radiation exposure in a cohort of male German uranium millers, 1946–2008." International Archives of Occupational and Environmental Health 88, no. 4 (August 19, 2014): 431–41. http://dx.doi.org/10.1007/s00420-014-0973-2.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

25

Cai, Ning, Junwei Cao, Minghua Liu, and Haiying Ma. "On Controllability Problems of High-Order Dynamical Multi-Agent Systems." Arabian Journal for Science and Engineering 39, no. 5 (March 1, 2014): 4261–67. http://dx.doi.org/10.1007/s13369-014-0973-2.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

26

Andreolio, Cinara, Jefferson Pedro Piva, Elisa Baldasso, Roberta Ferlini, and Rafaela Piccoli. "Prolonged infusion of dexmedetomidine in critically-ill children." Indian Pediatrics 53, no. 11 (November 2016): 987–89. http://dx.doi.org/10.1007/s13312-016-0973-2.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

27

Hallman, Birgit. "Gekonnt reagieren, wenn der Patient wütend ist." gynäkologie + geburtshilfe 21, no. 4 (July 2016): 44. http://dx.doi.org/10.1007/s15013-016-0973-2.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

28

Pasten, Hector. "Definability of Frobenius orbits and a result on rational distance sets." Monatshefte für Mathematik 182, no. 1 (September 21, 2016): 99–126. http://dx.doi.org/10.1007/s00605-016-0973-2.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

29

Li, Zhengkui, Yueming Wang, Ningmei Wu, Qichun Chen, and Kai Wu. "Removal of heavy metal ions from wastewater by a novel HEA/AMPS copolymer hydrogel: preparation, characterization, and mechanism." Environmental Science and Pollution Research 20, no. 3 (May 22, 2012): 1511–25. http://dx.doi.org/10.1007/s11356-012-0973-2.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

30

Ratha, Sachitra Kumar, Radha Prasanna, Vishal Gupta, Dolly Wattal Dhar, and Anil Kumar Saxena. "Bioprospecting and indexing the microalgal diversity of different ecological habitats of India." World Journal of Microbiology and Biotechnology 28, no. 4 (December 17, 2011): 1657–67. http://dx.doi.org/10.1007/s11274-011-0973-2.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

31

Komici, Klara, Grazia Daniela Femminella, Claudio de Lucia, Alessandro Cannavo, Leonardo Bencivenga, Graziamaria Corbi, Dario Leosco, Nicola Ferrara, and Giuseppe Rengo. "Predisposing factors to heart failure in diabetic nephropathy: a look at the sympathetic nervous system hyperactivity." Aging Clinical and Experimental Research 31, no. 3 (June 1, 2018): 321–30. http://dx.doi.org/10.1007/s40520-018-0973-2.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

32

Wolf, E., C. J. Kähler, D. R. Troolin, C. Kykal, and W. Lai. "Time-resolved volumetric particle tracking velocimetry of large-scale vortex structures from the reattachment region of a laminar separation bubble to the wake." Experiments in Fluids 50, no. 4 (September 16, 2010): 977–88. http://dx.doi.org/10.1007/s00348-010-0973-2.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

33

Chen, You-Shyang, Huan-Ming Chuang, Arun Kumar Sangaiah, Chien-Ku Lin, and Wen-Bin Huang. "A study for project risk management using an advanced MCDM-based DEMATEL-ANP approach." Journal of Ambient Intelligence and Humanized Computing 10, no. 7 (August 21, 2018): 2669–81. http://dx.doi.org/10.1007/s12652-018-0973-2.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

34

Teunissen, Cas, Jesse Habets, Birgitta K. Velthuis, Maarten J. Cramer, and Peter Loh. "Double-contrast, single-phase computed tomography angiography for ruling out left atrial appendage thrombus prior to atrial fibrillation ablation." International Journal of Cardiovascular Imaging 33, no. 1 (September 6, 2016): 121–28. http://dx.doi.org/10.1007/s10554-016-0973-2.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

35

Zauer, Mario, Anne Kowalewski, Robert Sproßmann, Holger Stonjek, and André Wagenführ. "Thermal modification of European beech at relatively mild temperatures for the use in electric bass guitars." European Journal of Wood and Wood Products 74, no. 1 (October 3, 2015): 43–48. http://dx.doi.org/10.1007/s00107-015-0973-2.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

36

Choi, Ki-Seon, Yu-Mi Cha, Sung-Dae Kang, and Hae-Dong Kim. "Interdecadal changes in TC activities that affect Korea." Theoretical and Applied Climatology 116, no. 3-4 (July 25, 2013): 491–500. http://dx.doi.org/10.1007/s00704-013-0973-2.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

37

Polyakov, A. Y., N. B. Smirnov, A. V. Govorkov, E. A. Kozhukhova, A. I. Belogorokhov, D. P. Norton, H. S. Kim, and S. J. Pearton. "Shallow and Deep Centers in As-Grown and Annealed MgZnO/ZnO Structures with Quantum Wells." Journal of Electronic Materials 39, no. 5 (November 18, 2009): 601–7. http://dx.doi.org/10.1007/s11664-009-0973-2.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

38

Karstoft, Karen-Inge, Cherie Armour, Søren B. Andersen, Mette Bertelsen, and Trine Madsen. "Community integration after deployment to Afghanistan: a longitudinal investigation of Danish soldiers." Social Psychiatry and Psychiatric Epidemiology 50, no. 4 (October 12, 2014): 653–60. http://dx.doi.org/10.1007/s00127-014-0973-2.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

39

Isobe, Shinsuke, Naro Ohashi, Tomoyuki Fujikura, Takayuki Tsuji, Yukitoshi Sakao, Hideo Yasuda, Akihiko Kato, Hiroaki Miyajima, and Yoshihide Fujigaki. "Disturbed circadian rhythm of the intrarenal renin-angiotensin system: relevant to nocturnal hypertension and renal damage." Clinical and Experimental Nephrology 19, no. 2 (April 12, 2014): 231–39. http://dx.doi.org/10.1007/s10157-014-0973-2.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

40

Ahmadiniaz, N., A. Bashir, and C. Schubert. "Multiphoton Amplitudes and Generalized LKF Transformation in Scalar QED Using the Worldline Formalism." Russian Physics Journal 59, no. 11 (March 2017): 1752–60. http://dx.doi.org/10.1007/s11182-017-0973-2.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

41

Risinger, Fred, and Janel Boyce. "Conditioning tastant and the acquisition of conditioned taste avoidance to drugs of abuse in DBA/2J mice." Psychopharmacology 160, no. 3 (March 1, 2002): 225–32. http://dx.doi.org/10.1007/s00213-001-0973-2.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

42

Miyaishi, S., M. Miura, K. Taniguchi, and K. Püschel. "„Verschwinden“ des Epiduralhämatoms im Verlauf." Rechtsmedizin 24, no. 5 (August 1, 2014): 418–20. http://dx.doi.org/10.1007/s00194-014-0973-2.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

43

Tranter, T. G., J. T. Gostick, A. D. Burns, and W. F. Gale. "Capillary Hysteresis in Neutrally Wettable Fibrous Media: A Pore Network Study of a Fuel Cell Electrode." Transport in Porous Media 121, no. 3 (December 1, 2017): 597–620. http://dx.doi.org/10.1007/s11242-017-0973-2.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

44

Mohieldin, Ahmed, Abdulmoneim Eldali, and Ali Aljubran. "Knowledge, Perception, and Attitudes of Cancer Patients Towards Cancer and Cancer Care: Local Perspective from Saudi Arabia." Journal of Cancer Education 32, no. 2 (January 23, 2016): 314–19. http://dx.doi.org/10.1007/s13187-015-0973-2.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

45

Bellos, I., G. Fitrou, V. Pergialiotis, D. N. Perrea, and G. Daskalakis. "Serum levels of adipokines in gestational diabetes: a systematic review." Journal of Endocrinological Investigation 42, no. 6 (November 3, 2018): 621–31. http://dx.doi.org/10.1007/s40618-018-0973-2.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

46

de Carvalho Pinto, P. C., M. M. de Oliveira Carvalho, F. M. Linhares, T. R. da Silva, and G. M. de Lima. "A cleaner production of sodium hydrogen carbonate: partial replacement of lime by steel slag milk in the ammonia recovery step of the Solvay process." Clean Technologies and Environmental Policy 17, no. 8 (May 23, 2015): 2311–21. http://dx.doi.org/10.1007/s10098-015-0973-2.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

47

Bisdas, Sotirios, Zoran Rumboldt, Katarina Surlan, Tong San Koh, John Deveikis, and Maria Vittoria Spampinato. "Perfusion CT measurements in healthy cervical spinal cord: feasibility and repeatability of the study as well as interchangeability of the perfusion estimates using two commercially available software packages." European Radiology 18, no. 10 (April 23, 2008): 2321–28. http://dx.doi.org/10.1007/s00330-008-0973-2.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

48

Wu, Jia, Zilin Xu, Yixuan Pan, Yi Shi, Xiujie Bao, Jun Li, Yu Tong, et al. "Combination of in situ metathesis reaction with a novel “magnetic effervescent tablet-assisted ionic liquid dispersive microextraction” for the determination of endogenous steroids in human fluids." Analytical and Bioanalytical Chemistry 410, no. 12 (March 12, 2018): 2921–35. http://dx.doi.org/10.1007/s00216-018-0973-2.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

49

Hassan, Jihaan, Jan Jaap van der Net, and Annet van Royen-Kerkhof. "Treatment of refractory juvenile dermatomyositis with tacrolimus." Clinical Rheumatology 27, no. 11 (August 21, 2008): 1469–71. http://dx.doi.org/10.1007/s10067-008-0973-2.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

50

Van Gorder, Robert A., K. V. Prasad, and K. Vajravelu. "Convective heat transfer in the vertical channel flow of a clear fluid adjacent to a nanofluid layer: a two-fluid model." Heat and Mass Transfer 48, no. 7 (January 18, 2012): 1247–55. http://dx.doi.org/10.1007/s00231-012-0973-2.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

Ми пропонуємо знижки на всі преміум-плани для авторів, чиї праці увійшли до тематичних добірок літератури. Зв'яжіться з нами, щоб отримати унікальний промокод!